PRRT And The Neuroendocrine Tumor Treatment Algorithm

Data from 2 NETTER trials support lutetium Lu 177 dotatate's approval in somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.

Ahead of the 2015 ASCO Annual Meeting, we are discussing over-the-counter therapies for patients with metastatic colorectal cancer with Andrew T. Chan, MD, MPH.

Data from the phase 3 NETTER-2 trial support the frontline use of Lutetium Lu 77 dotatate well-differentiated gastroenteropancreatic neuroendocrine tumors.

As part of our coverage of the ASCO Annual Meeting, we discuss advances in the management of upper gastrointestinal (GI) tract tumors, as well as highlighting clinical trial results that will be reported at the meeting.

Cabozantinib may become a new treatment option for those with previously treated advanced neuroendocrine tumors based on data from the phase 3 CABINET trial.

Over half of all patients with small cell neuroendocrine prostate cancer treated with BXCL701 and pembrolizumab were alive at 1 year in a phase 2 trial.